Mikhail Blagosklonny: What Causes Aging?

Education and Career Background

Mikhail Blagosklonny is an oncology professor, employed at the prestigious Roswell Cancer Institute. One of the most famous of his works is the theory that seeks to relate aging with cancer. He graduated with a medical degree from the First Pavlov State Medical University of St. Petersburg, Russia. Later, he attained a doctorate in cardiology and experimental medicine from the same institution.

He started practicing as an associate professor at the New York Medical College. Ordway research was the next stop for him, a position he held until 2009. He later joined Roswell where he has rose through the ranks and become a leading oncology researcher.

The Role of TOR in the Aging Process

Contrary to popular belief, aging is not caused by damages resulting from pathogens, stress or physical injuries and impacts. Mikhail Blagosklonny has come with a theory that seeks to abolish the belief that aging is as a consequence of the agglomeration of cellular damages. Visit ResearchGate to keep up to date with Mikhail’s latest work.

Through research, Mikhail has established that TOR (Target of Rapamycin) signaling plays a significant part in the acceleration of aging. Though the accumulation of cellular damage might be partially correct, Mikhail argues that most organisms die before the injuries deplete the cells. He says that his research has proven that TOR is an aging catalyst. In a normal human being, Tor stimulates cell growth, which is kept in check by cell division, however, when the cell division fails due to other factors and TOR is still active, cells start to malfunction. As a result conditions such as high blood pressure, cancers, Alzheimer’s, and other old age diseases start affecting the patient.

A remedy to this catastrophe is slowing down aging or increasing age tolerance. Since TOR causes aging, inhibiting its pathway and taking Rapamycin which has proven to extend lives of yeast and mice, can significantly elongate life. Rapamycin works by ensuring the cellular cycle does not fail, resulting in cellular senescence. Physical exercise also considerably contributes towards aging inhibition.

Age tolerance can be increased by inducing damaging stresses. This protects humans from the harmful consequences of aging-related diseases by familiarizing their immune systems with the causative agents.

Oncology Literature

Owing to his extensive research on the subject, Mikhail is one of the most prominent figures in oncology. In his illustrious career, he has written several editorials on oncology and aging. His publications are popular, having received over 30,000 citations from his peers.

View Mikhail’s profile on Loop

JeanMarie Guenot: Restoring The Flow Of Life

JeanMarie Guenot, PhD., is the President and Chief Executive Officer of Amphivena Therapeutics Inc. The company started its operations in July 2013 and is dedicated to the development of innovative therapies specifically for hematologic malignancies. The San Francisco based company is a preclinical stage based Research Company and its Research and Development team is in the process of development of a first-in-class bi-functional antibody therapy to address the blood cancer indications with high unmet medical needs. Amphivena Therapeutics, Inc. has a motto that aptly summarizes the mission of the company which reads “Restoring the flow of life.”

JeanMarie has tremendous expertise in many fields including venture capital, project and alliance management, corporate and commercial development, business development, and pharmaceutical research and development. Her experience spans through all stages of company development in both private and public companies. JeanMarie got her PhD. from University of California, San Francisco in 1993after which she joined Hoffman- La Roche as the Team Leader/ Principal Scientist of Preclinical Research and Development department, a position whose roles involved the discovery and development of drugs for inflammation, metabolic diseases, oncology and autoimmune diseases. She stayed in this position until 1999 and in 2000 she joined Atlas Venture, a venture capital and private equity firm where she held the position of Associate in Life Sciences.

JeanMarie left Atlas Venture in 2003 and joined PDL Biopharma, a biotechnology firm, as Vice President of Corporate and Business Development. At PDL she was in charge of licensing, mergers and acquisitions and alliance management for the Research and Development department. She remained in this position until 2008 when she became Managing Partner at Guenot LLC. In 2009, JeanMarie was working at SKS Ocular, LLC. At SKS Ocular, she was a Founder, Partner, and First Employee, where she focused on ophthalmology as the key Operating Officer up until 2012.

As CEO of Amphivena Therapeutics, JeanMarie has overseen the milestones surpassed by the Research and Development Department with the latest news concerning Acute Myeloid Leukemia. The company has focused on using tetravalent bispecific CD33/CD3 TandAbs for in vivo and in vitro killing of Acute Myeloid Laukemia.

JeanMarie Guenot’s achievements have received the recognition they deserve and in 2005 she received the BioBusiness Network’s Innovative Bio-Partnering Award and in 2006 the Licensing Executives Society awarded her the Deal of Distinction. Under Guenot’s capable leadership, Amphivena Therapeutics is making headway in providing cutting edge development research aimed at blood cancer, a disease that takes a toll on those afflicted and this effort is commendable and deserves more recognition.

Jeanmarie Guenot’s company Amphivena Therapeutics was also named one of the top 10 Bay Area biotech startups in BioSpace’s article:
http://www.biospace.com/News/the-10-hottest-bay-area-biotech-startups/391820

 

Oncotarget: Highest Ranked Online Medical Oncology Research Journal

Oncotarget was established in 2010 and is a multi-disciplinary, traditional, free-access medical journal that publishes weekly papers online. Editors-in-Chief Mikhail Bagosklonny and Andrei V. Gudklov work with the most prominent scientists to aid in the research towards the progress of science and medicine. Their end goal is a disease-free life for everyone.

The journal has been so successful that the editorial staff decided to expand beyond the sole study of Oncology. The journal now accepts papers on all areas of Pharmacology on scijournal.org. In addition, papers on research of Aging, Immunology, Microbiology, Neuroscience, Endocrinology, Cardiology, and Metabolism are accepted.

Current and archived journals can be located on the Oncotarget home page which is found at www.impactjournals.com. Rules for publishing a paper,as well as contact information for the journal, can be found on the home page, as well. Oncotarget follows the COPE Code of Conduct as well as COPE General Guidelines. Authors are also required to follow the Best Practice Guidelines for Journal Editors and the Code of Conduct for Journal Publishers, as well as relevant general guidelines from Elsevier and it’s journals. All editors, authors, and reviewers are required to follow the best-practice guidelines on ethical behavior ICMJE’s Recommendation’s for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals on Facebook.

Gregg Semenza, professor of pediatrics, radiation oncology, biological chemistry, medicine, and oncology at Johns Hopkins School of Medicine , has published 7 papers of the 370 oxygen related papers on Oncotarget.

The papers published on Oncotarget are available to the general public and, each issue or paper can be printed upon request on Bioxbio.com. Oncotarget’s primary focus is cancer research and oncology. However, because tumor development is extremely complex, the journal also publishes papers on endocrinology, pathology, age-related diseases and illnesses, physiology, and immunology.

In order to submit a paper, an account must be created and the user must be logged into the site. After a manuscript is submitted, editors assign reviewers to the paper. After extensive review at http://endnote.com/downloads/style/oncotarget , the editor drafts a decision to the author. Pertinent information, such as first and last names, postal addresses, and email addresses, must be gathered prior to each submission. Authors must follow guidelines and code of ethic for papers to be accepted.